Emergingby GlyphLoyal's large-dog lifespan drug LOY-003 earns FDA RXE
LOY-003 became Loyal's third program to earn Reasonable Expectation of Effectiveness from the FDA.
Longevity biotechloyal.com
Loyal
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechVeterinary drug company developing FDA-approved lifespan extension drugs for dogs. | Veterinary drug company developing FDA-approved lifespan extension drugs for dogs. | loyal.com |
Events
FDA accepts safety section for Loyal's LOY-002
The FDA's veterinary center accepted the target animal safety section of LOY-002's conditional approval file.
Longevity biotechloyal.com
Loyal completes enrollment of the STAY study at 1,300 dogs
The LOY-002 trial enrolled 1,300 dogs across more than 70 clinics.
Longevity biotechloyal.com
Loyal's STAY study enrolls 1,000 dogs
The LOY-002 trial hit its enrollment goal and expanded to up to 1,300 dogs.
Longevity biotechloyal.com
FDA accepts efficacy case for Loyal's senior dog lifespan drug
LOY-002 earned Reasonable Expectation of Effectiveness from the FDA, Loyal's second RXE.
Longevity biotechloyal.com
Loyal doses the first dog in its LOY-002 pivotal lifespan study
A senior dog named Boo became the first dog dosed in the STAY study of LOY-002.
Longevity biotechloyal.com
Funding
About
- Source
- loyal.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- Loyal on Companies